



Company Contact:
Jie Du, Ph.D.
President & CEO
JDP THERAPEUTICS, INC.
Email: jiedu@jdptherapeutics.com
www.jdptherapeutics.com

Dr. Benjamin Abella Joins JDP's Medical Advisory Board

BLUE BELL, PENNSYLVANIA, October 16, 2012 – JDP Therapeutics Inc., a privately held clinical stage specialty pharmaceutical company, is pleased to announce that Benjamin S. Abella, M.D., MPhil, an expert in Emergency Medicine, has joined JDP Therapeutics' Medical Advisory Board. Dr. Abella will be providing key medical guidance and support to the Company's planned clinical trials in the field of Emergency Medicine for the treatment of acute allergic reactions and anaphylaxis.

Dr. Abella is a practicing emergency physician at the Hospital of the University of Pennsylvania, and the Clinical Research Director of the Center for Resuscitation Science at the University of Pennsylvania. He maintains a vigorous research program in emergency care, with support from the NIH, Medtronic foundation and industry sources. He has published over 100 original peer reviewed manuscripts, book chapters and editorials, and is a prolific speaker at national and international meetings on emergency care. Dr. Abella received his M.D. from Johns Hopkins School of Medicine,

About JDP Therapeutics Inc.

JDP Therapeutics Inc. is a privately held, clinical stage specialty pharmaceutical company focused on developing small molecule therapeutics to treat life threatening diseases with significant unmet medical needs, primarily for use of acute care in the hospital setting.

JDP Therapeutics pursues unfulfilled opportunities in existing molecules from which it develops unique dosage forms, novel formulations, and new indications to achieve full therapeutic and market potential. This approach mitigates risk, shortens development cycle, leads to a well-defined regulatory pathway, and fully characterizes clinical needs for each product opportunity.

For further information, please email info@jdptherapeutics.com

###

Safe Harbor Statement Regarding Forward-looking Statements

The statements in this release and oral statements made by representatives of JDP relating to matters that are not historical facts (including without limitation those regarding the timing or potential outcomes of research or clinical trials, any market that might develop for any of JDP's product candidates are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of JDP and/or its partners to develop, manufacture and commercialize, JDP's ability to fund such efforts with or without partners, and other risks.